Arrowhead Pharmaceuticals, Inc. (ARWR)
85.40
+2.66
(+3.21%)
USD |
NASDAQ |
Sep 02, 16:00
85.00
-0.40
(-0.47%)
After-Hours: 20:00
Arrowhead Pharmaceuticals Research and Development Expense (TTM) : 699.56M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 699.56M |
| March 31, 2026 | 664.16M |
| December 31, 2025 | 624.30M |
| September 30, 2025 | 585.26M |
| June 30, 2025 | 547.85M |
| March 31, 2025 | 539.36M |
| December 31, 2024 | 508.85M |
| September 30, 2024 | 489.22M |
| June 30, 2024 | 454.22M |
| March 31, 2024 | 397.95M |
| December 31, 2023 | 373.54M |
| September 30, 2023 | 342.31M |
| June 30, 2023 | 327.03M |
| March 31, 2023 | 305.13M |
| December 31, 2022 | 306.31M |
| September 30, 2022 | 288.50M |
| June 30, 2022 | 270.66M |
| March 31, 2022 | 258.58M |
| December 31, 2021 | 227.73M |
| September 30, 2021 | 199.02M |
| June 30, 2021 | 177.60M |
| March 31, 2021 | 150.89M |
| December 31, 2020 | 136.16M |
| September 30, 2020 | 123.54M |
| June 30, 2020 | 103.99M |
| Date | Value |
|---|---|
| March 31, 2020 | 91.09M |
| December 31, 2019 | 82.49M |
| September 30, 2019 | 76.63M |
| June 30, 2019 | 69.09M |
| March 31, 2019 | 61.68M |
| December 31, 2018 | 52.91M |
| September 30, 2018 | 44.94M |
| June 30, 2018 | 38.45M |
| March 31, 2018 | 34.48M |
| December 31, 2017 | 30.60M |
| September 30, 2017 | 31.69M |
| June 30, 2017 | 35.08M |
| March 31, 2017 | 37.60M |
| December 31, 2016 | 40.64M |
| September 30, 2016 | 41.45M |
| June 30, 2016 | 40.17M |
| March 31, 2016 | 38.24M |
| December 31, 2015 | 39.86M |
| September 30, 2015 | 47.26M |
| June 30, 2015 | 45.29M |
| March 31, 2015 | 44.20M |
| December 31, 2014 | 37.77M |
| September 30, 2014 | 23.16M |
| June 30, 2014 | 17.99M |
| March 31, 2014 | 13.35M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Sarepta Therapeutics, Inc. | 783.60M |
| Revolution Medicines, Inc. | 1.287B |
| Moderna, Inc. | 2.635B |
| Intellia Therapeutics, Inc. | 337.63M |
| Denali Therapeutics, Inc. | 400.72M |